Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company developing small-molecule therapies for cystic fibrosis (CF), a genetic disease caused by impaired cystic fibrosis transmembrane conductance regulator (CFTR) protein function. Its approach centers on stabilizing CFTR’s nucleotide… From the company’s description.
In fiscal 2025, Sionna Therapeutics, Inc. reported a net loss of $75.27M. Operations used $66.30M in cash.
Dotted labels explain each measure. is shown separately from the annual figures.
What Sionna Therapeutics, Inc. does
In the company’s own words
Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company developing small-molecule therapies for cystic fibrosis (CF), a genetic disease caused by impaired cystic fibrosis transmembrane conductance regulator (CFTR) protein function. Its approach centers on stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which is affected by the common F508del mutation, and developing complementary CFTR modulators for combination treatment. The company’s lead NBD1 stabilizers are SION-719, being evaluated in a Phase 2a trial as an add-on to standard-of-care Trikafta, and SION-451, being tested in Phase 1 dual combinations with SION-2222 and SION-109. Its complementary portfolio includes SION-2222 and SION-109, both correctors, SION-2851, a corrector, and SION-3067, a potentiator. Sionna’s development programs use a human bronchial epithelial cell model to assess CFTR function and guide compound selection. The company is focused on research and development and has no commercialized products described in its business overview.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 2036042
- SIC
- 2834
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Sionna Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Sionna Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Sionna Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Sionna Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Sionna Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”